TrialsgrambetaRCTs are beautiful

REPRISE

2017

Tolvaptan Safety and Efficacy in Later-Stage ADPKD

In 1,370 patients with later-stage ADPKD, tolvaptan slowed eGFR decline compared with placebo.

Result

Primary endpoint: Change in eGFR from baseline

−2.34 vs −3.61 mL/min/1.73m²/yr; difference 1.27 (95% CI 0.86–1.68; p<0.001).

Original publication
Subtopic
ADPKD
Design
Double-blind RCT over 12 months
Relevance
Supporting: context rather than must-know.
Source
Torres VE, et al. N Engl J Med. 2017;377(20):1930-1942.doi 10.1056/NEJMoa1710030

Discussion & critique

Extended the tolvaptan indication to more advanced CKD stages of ADPKD.

Discussed in podcasts